Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 14;11(4):704.
doi: 10.3390/diagnostics11040704.

Evaluation of the Potential Diagnostic Utility of the Determination of Selected Caspases-Markers Involved in the Regulation of Apoptosis-In Patients with Ovarian Cancer

Aleksandra Mielczarek-Palacz  1 , Sylwia Jasińska  1 , Anna Strzelec  1
Affiliations

Evaluation of the Potential Diagnostic Utility of the Determination of Selected Caspases-Markers Involved in the Regulation of Apoptosis-In Patients with Ovarian Cancer

Aleksandra Mielczarek-Palacz et al. Diagnostics (Basel). .

Abstract

Ovarian cancer remains a major diagnostic and therapeutic problem in modern gynecological oncology. For this reason, research which focuses on the search for new diagnostic markers and the assessment of their possible usefulness in clinical practice is still being conducted. The aim of this study was to evaluate serum levels of caspase-3, caspase-8, and caspase-9 in women with ovarian cancer. Patients with ovarian serous cystadenoma (Cystadenoma serosum) and papillary serous cystadenocarcinoma (Cystadenocarcinoma papillare serosum IIIC) were included in the study, as well as healthy women who constituted the control group. The results of the study revealed a statistically significantly decreased mean serum levels of caspase-3, caspase-8, and caspase-9 in women with ovarian cancer as compared to the control group (p ˂ 0.001), which indicates the involvement of the studied parameters in immune system disturbances occurring in the process of apoptosis by the extrinsic and intrinsic pathway and may be one of the mechanisms of immunosuppression accompanying these tumors. Determination of serum levels of examined caspases and CA 125 antigen in women with ovarian cancer in combination with other markers may prove useful in the future in the diagnosis of ovarian cancer, but this requires further studies.

Keywords: apoptosis; caspase-3; caspase-8; caspase-9; ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mean serum caspase-3 levels in women with ovarian serous cystadenoma, ovarian serous cystadenocarcinoma, and control group.
Figure 2
Figure 2
Linear regression curve showing the relationship between caspase-3 concentration and the decimal logarithm of CA 125 antigen concentration in the blood serum of women with ovarian cancer.
Figure 3
Figure 3
Receiver Operating Characteristic (ROC) curve of caspase-3 and ROC curve of CA 125 antigen.
Figure 4
Figure 4
Mean serum caspase-8 levels in women with ovarian serous cystadenoma, ovarian serous cystadenocarcinoma, and control group.
Figure 5
Figure 5
Linear regression curve showing the relationship between caspase-8 concentration and the decimal logarithm of CA 125 antigen concentration in the blood serum of women with ovarian cancer.
Figure 6
Figure 6
ROC curve of caspase-8 and ROC curve of CA 125 antigen.
Figure 7
Figure 7
Mean serum caspase-9 levels in women with ovarian serous cystadenoma, ovarian serous cystadenocarcinoma, and control group.
Figure 8
Figure 8
Linear regression curve showing the relationship between caspase-9 concentration and the decimal logarithm of CA 125 antigen concentration in the blood serum of women with ovarian cancer.
Figure 9
Figure 9
ROC curve of caspase-9 and ROC curve of CA 125 antigen.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. McMullen M., Karakasis K., Rottapel R., Oza A.M. Advances in ovarian cancer, from biology to treatment. Nat. Cancer. 2021;2:6–8. doi: 10.1038/s43018-020-00166-5. - DOI - PubMed
    1. Wei W., Li N., Sun Y., Li B., Xu L., Wu L. Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer. Oncotarget. 2017;8:23862–23870. doi: 10.18632/oncotarget.13317. - DOI - PMC - PubMed
    1. Kossai M., Leary A., Scoazec J.Y., Genestie C. Ovarian Cancer: A Heterogeneous Disease. Pathobiology. 2018;85:41–49. doi: 10.1159/000479006. - DOI - PubMed
    1. Docher V., Caillon H., Vaucel E., Dimet J., Winer N., Ducarme G. Biomarkers and algorithms for diagnosis in ovarian cancer: CA 125, HE4, RMI and ROMA, a review. J. Ovarian Res. 2019;12:28. doi: 10.1186/s13048-019-0503-7. - DOI - PMC - PubMed
    1. Stenman U.H. Biomarker development, from bench to bedside. Crit. Rev. Clin. Lab. Sci. 2016;53:69–86. doi: 10.3109/10408363.2015.1075468. - DOI - PubMed

LinkOut - more resources